Study on First-Line Treatment with Ipilimumab, Nivolumab, and Nogapendekin Alfa Inbakicept for Stage IV or Recurrent Non-Small Cell Lung Cancer

Inclusion Criteria

• Have a confirmed diagnosis of advanced or returning non-small cell lung cancer (NSCLC) that has not been treated before.
• Be willing to provide a previous biopsy sample or undergo a new biopsy for testing.
• Have measurable cancer according to specific medical criteria.
• Be at least 18 years old.
• Be in good overall health with a performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have adequate organ and bone marrow function, as shown by specific blood test results.
• If you have brain metastases, they must have been treated and stable for at least two weeks without needing high doses of steroids.
• Agree to use effective birth control during the study and for six months after the last treatment dose if you can become pregnant or father a child.
• Be able to understand and sign a consent form to participate in the study.

Exclusion Criteria

• Have a type of lung cancer that includes small cell lung cancer.
• Have tumors with specific genetic mutations, such as EGFR, HER2, ALK, ROS1, RET, NTRK, MET, or BRAF mutations.
• Have received live vaccines within 28 days before starting the study.
• Have had chemotherapy or radiation therapy for lung cancer within the past 12 months, unless it was more than 12 months ago.
• Have had major surgery within 14 days before starting the study.
• Have certain medical conditions that could make the study treatment unsafe, such as lung disease, active infections, or significant heart problems.
• Be taking high doses of steroids or other immune-suppressing medications.
• Have HIV, hepatitis B, or hepatitis C infections that are not well-controlled.
• Have a history of autoimmune diseases that required treatment in the past two years, except for certain conditions like vitiligo or resolved childhood asthma.
• Have other active cancers that could interfere with the study.
• Be pregnant or breastfeeding, or planning to become pregnant during the study.
• Have a history of severe allergic reactions to similar drugs used in the study.